Myth Check · DXA Evidence

Retatrutide & Muscle: What the DXA Data Really Shows

📄 7 PubMed citations

Viral threads claim GLP-1s strip up to 39% of your weight as muscle and demand a gram of protein per pound. Here is what the controlled body-composition evidence actually supports — and the protein-plus-training plan that protects lean mass on retatrutide.

🔬 Unlike our general GLP-1 muscle-loss guide, this page is retatrutide-specific and myth-focused: it separates the viral "first DXA scan" and "39% muscle" claims from the peer-reviewed DXA trial data, and gives an evidence-based (not heuristic) protein and resistance-training target.
25%
of tirzepatide weight loss was lean mass on DXA — the same share as placebo
46%
of fat-free mass loss prevented by adding resistance training
1.6 g/kg
evidence-based upper daily protein target to protect lean mass

How It Works

🔥
Any large weight loss sheds lean mass

In the SURMOUNT-1 DXA substudy, about 75% of the weight lost was fat and 25% was lean mass — and that fat-to-lean ratio was the same in the placebo group. Losing weight, not the drug itself, is what reduces lean mass.

🧬
Lean mass is not skeletal muscle

DXA "lean mass" and BIA "fat-free mass" include water, glycogen, organs and connective tissue. Reviews stress that a drop in lean tissue does not necessarily mean lost strength or physical function.

🍗
Protein defends the muscle you keep

Guideline-informed targets during GLP-1 weight loss are at least 1.2 g/kg/day (up to about 1.6 g/kg in adults without kidney disease), spread ~0.3–0.4 g/kg per meal with roughly 2.5–3 g of leucine each.

🏋️
Resistance training is the strongest lever

Across 34 randomized trials, adding exercise to calorie restriction preserved about 0.87 kg more fat-free mass — cutting would-be loss by roughly 46%, with mixed and strength training the most effective.

What the Data Shows

Fat mass lost (tirzepatide)
SURMOUNT-1 DXA substudy, Week 72
~75% of weight lost
Lean mass lost (tirzepatide)
includes water, glycogen, organs — not just muscle
~25% of weight lost
Lean mass lost (placebo / diet only)
same fat-to-lean ratio as the drug group
~25% of weight lost
Muscle loss prevented by resistance training
34-RCT meta-analysis, +0.87 kg fat-free mass
~46% of would-be loss
Retatrutide weight loss (Phase 2, 12 mg, 48 wk)
NEJM 2023 triple-agonist trial
-24.2% body weight

Key Takeaways

✅ What We Know
  • In the best-controlled DXA data available (tirzepatide, SURMOUNT-1), about 25% of the weight lost was lean mass — and that share was the same as in the placebo group.
  • DXA "lean mass" and BIA "fat-free mass" are not the same as skeletal muscle; they include water, glycogen, organs and connective tissue, so a scan drop does not automatically mean lost strength.
  • Protein of at least 1.2 g/kg/day (up to ~1.6 g/kg in adults without kidney disease), spread ~0.3–0.4 g/kg per meal with ~2.5–3 g leucine, is the guideline-informed target for protecting lean tissue.
  • Adding resistance or mixed training to calorie restriction prevents roughly 46% of the fat-free mass you would otherwise lose (+0.87 kg across 34 RCTs).
  • Retatrutide (LY3437943) is a GIP/GLP-1/glucagon triple agonist; its Phase 2 trial reached about -24% body weight at 48 weeks on the 12 mg dose.
  • Older adults, people with sarcopenic obesity, and those with type 2 diabetes are at greatest risk from lean-mass loss and benefit most from a protein-plus-training plan.
⚠️ What We Don't Know
  • No peer-reviewed DXA body-composition trial of retatrutide has been published yet — viral "first DXA scan data" claims are not from a controlled trial, so retatrutide’s exact fat-to-lean split is still unknown and extrapolated from same-class drugs.
  • It is not established that a "1 gram of protein per pound of goal bodyweight" target (~2.2 g/kg) beats the evidence-based ~1.2–1.6 g/kg — the higher intake is a popular heuristic, not a trial-tested requirement.
  • Whether the lean mass lost translates into meaningful, lasting loss of strength or physical function for most users is not established.
  • Long-term (multi-year) effects of GLP-1-driven lean-mass changes on frailty and sarcopenia risk are still being studied.

Frequently Asked Questions

Does retatrutide cause more muscle loss than other GLP-1 drugs?

There is no published DXA trial of retatrutide yet, so its exact fat-to-lean split is unknown. In the closest comparison — tirzepatide’s SURMOUNT-1 DXA substudy — about 25% of the weight lost was lean mass, the same proportion as diet-only placebo. Any large weight loss reduces lean mass; there is no evidence retatrutide is uniquely worse.

Is 39% of the weight I lose on a GLP-1 really muscle?

That framing overstates it. The best-controlled DXA data put lean-mass loss near 25% of total weight lost, and "lean mass" is not the same as muscle — it also includes water, glycogen and organ tissue. Higher single figures exist but conflate lean mass with skeletal muscle.

How much protein should I eat to keep muscle on retatrutide?

Guideline-informed targets are at least 1.2 g/kg of body weight per day, up to about 1.6 g/kg in adults without kidney disease, spread across meals (~0.3–0.4 g/kg each) with roughly 2.5–3 g of leucine per meal.

Does lifting weights actually preserve muscle during GLP-1 weight loss?

Yes. Across 34 randomized trials, adding resistance or mixed training to calorie restriction preserved about 0.87 kg more fat-free mass — cutting would-be lean-mass loss by roughly 46%. Mixed and strength training worked best.

Should I get a DXA scan while on retatrutide?

DXA (or BIA) is the practical way to track whether you are losing fat versus lean tissue over time. Reviews recommend risk-based body-composition monitoring, especially for older adults and people with type 2 diabetes.

🔬 Research-Grade Source

Swiss Chems publishes third-party HPLC COAs for selected products — vendor-published, a claim to verify. HighPeptides' primary vendor reference for peptides.

Browse Swiss Chems →
Code HIGHPEP10 — 10% off regular-priced items

Affiliate links — support HighPeptides at no extra cost.

Peer-Reviewed References

Source 1
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial
N Engl J Med · 2023
PMID: 37366315
Source 2
Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight
Diabetes Obes Metab · 2025
PMID: 39996356
Source 3
Lean Mass and Musculoskeletal Preservation in GLP-1-Based Obesity Treatment: Nutrition, Exercise, Supplementation, and Monitoring Strategies
Metabolites · 2026
PMID: 42346344
Source 4
Medical nutrition in the GLP-1 era: Protein strategies, micronutrient monitoring, and lean mass preservation
Clin Nutr ESPEN · 2026
PMID: 42036071
Source 5
Effects of Calorie Restriction With and Without Strength, Endurance or Mixed Training on Fat-Free and Skeletal Muscle Mass in Overweight or Obese Individuals
Diabetes Obes Metab · 2026
PMID: 42144246
Source 6
Optimizing Weight Loss in the GLP-1 Era: Preserving Muscle Mass, Function and Metabolic Health Through Precision Nutrition and Resistance Training
Pharmaceuticals (Basel) · 2026
PMID: 42356514
Source 7
Preventive Strategies to Reduce Sarcopenia Risk During GLP-1-Based Anti-Obesity Therapy
J Clin Med · 2026
PMID: 42589975
⚠️ Disclaimer

Educational purposes only. Not medical advice.

Retatrutide is an investigational compound not approved by the FDA for weight loss; discuss any medication or body-composition plan with a qualified clinician.